PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17138749-8	2006	Small-animal PET revealed rapid, specific, and prominent uptake of (64)Cu-DOTA-VEGF(121) in small U87MG tumors (high VEGFR2 expression) but significantly lower and sporadic uptake in large U87MG tumors (low VEGFR2 expression).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	71-78	kinase insert domain receptor	Homo sapiens	117-123	
17138749-8	2006	Small-animal PET revealed rapid, specific, and prominent uptake of (64)Cu-DOTA-VEGF(121) in small U87MG tumors (high VEGFR2 expression) but significantly lower and sporadic uptake in large U87MG tumors (low VEGFR2 expression).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	71-78	kinase insert domain receptor	Homo sapiens	207-213	
17138749-10	2006	Blocking experiments, immunofluorescence staining, and western blot confirmed the VEGFR specificity of (64)Cu-DOTA-VEGF(121).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	107-114	kinase insert domain receptor	Homo sapiens	82-87	
17138749-11	2006	CONCLUSION: Successful demonstration of the ability of (64)Cu-DOTA-VEGF(121) to visualize VEGFR expression in vivo may allow for clinical translation of this radiopharmaceutical for imaging tumor angiogenesis and guiding antiangiogenic treatment, especially patient selection and treatment monitoring of VEGFR-targeted cancer therapy.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	62-66	kinase insert domain receptor	Homo sapiens	90-95	
17138749-11	2006	CONCLUSION: Successful demonstration of the ability of (64)Cu-DOTA-VEGF(121) to visualize VEGFR expression in vivo may allow for clinical translation of this radiopharmaceutical for imaging tumor angiogenesis and guiding antiangiogenic treatment, especially patient selection and treatment monitoring of VEGFR-targeted cancer therapy.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	62-66	kinase insert domain receptor	Homo sapiens	304-309